InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 426.32% from the stock’s current price.

InflaRx Stock Performance

InflaRx stock opened at $1.52 on Monday. InflaRx has a fifty-two week low of $1.17 and a fifty-two week high of $2.10. The company has a market capitalization of $89.50 million, a price-to-earnings ratio of -1.41 and a beta of 1.57. The stock has a fifty day moving average of $1.52 and a two-hundred day moving average of $1.51.

Institutional Inflows and Outflows

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC increased its position in shares of InflaRx (NASDAQ:IFRX) by 2.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the quarter. Ikarian Capital LLC owned approximately 1.20% of InflaRx worth $1,086,000 as of its most recent filing with the SEC. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.